Mindbloom vs. Spravato: 7 Key Differences in Depression Treatment

Mindbloom vs. Spravato at a Glance

Both Mindbloom and Spravato use ketamine to treat depression, but they differ structurally on every dimension that matters for a treatment decision. Spravato is a branded esketamine nasal spray administered in a REMS-certified clinic with a mandatory two-hour observation period. Mindbloom is a guided at-home program combining racemic ketamine (sublingual tablets or subcutaneous injection) with clinician oversight, coaching, and integration support.

The two treatments also differ on their clinical evidence base. Mindbloom's published outcomes draw from the largest real-world peer-reviewed ketamine studies to date (Mathai 2024, n=11,441; Hull 2022, n=1,247).^1,2 Spravato's evidence base comes from its FDA approval package, which includes one positive efficacy trial (TRANSFORM-2), two failed efficacy trials (TRANSFORM-1 and TRANSFORM-3 in elderly patients), two trials in patients with suicidal ideation that did not meet their suicidality endpoints (ASPIRE-1 and ASPIRE-2), and a relapse-prevention trial (SUSTAIN-1).^{14,15,16,17,18,20}

Mindbloom vs. Spravato Side-by-Side Comparison Table

What Is Spravato?

Spravato is the brand name for esketamine, a nasal spray derived from the S-enantiomer of ketamine. It received FDA approval in 2019 for adults with treatment-resistant depression, and in 2020 for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.

Under the Spravato REMS program, treatment is administered at a certified healthcare facility with required post-dose monitoring. These facilities must be enrolled in the Spravato REMS (Risk Evaluation and Mitigation Strategy) program to ensure patient safety.

Each session involves self-administering the ketamine nasal spray dosage under direct medical supervision. This is followed by a mandatory two-hour observation period during which your blood pressure is monitored.

A typical Spravato session includes:

• Arrival: Checking in at a REMS-certified clinic.
• Administration: Self-administering the nasal spray under observation.
• Observation: A two-hour mandatory monitoring period.
• Discharge: Arranging transportation home from the clinic, as patients cannot drive themselves home.

Spravato's FDA-approved status means it has undergone randomized controlled trials for its specific indications. However, the in-clinic requirement creates logistical considerations, as patients must arrange transportation and block several hours per visit.

Spravato's FDA approval rests on five Phase 3 pivotal trials. One efficacy trial (TRANSFORM-2, n=227) met its primary endpoint with an effect size of d=0.30, classified as "small" by standard clinical research conventions.¹⁵ Two efficacy trials (TRANSFORM-1, n=346, and TRANSFORM-3 in elderly patients, n=138) did not meet their primary endpoints.^14,16 Two trials in patients with active suicidal ideation (ASPIRE-1, n=226, and ASPIRE-2, n=230) showed improvement in depression scores but did not meet their primary suicidality endpoints.^17,18 A long-term relapse-prevention trial (SUSTAIN-1) met its endpoint using a randomized withdrawal design that has drawn methodological criticism in the peer-reviewed literature.²⁰

What Is Mindbloom Guided At-Home Ketamine Therapy?

Mindbloom is a guided at-home ketamine therapy provider delivering clinician-supervised treatment for depression, anxiety, PTSD, and related conditions. Ketamine is prescribed off-label by Mindbloom's licensed clinicians for mental health indications.

Off-label prescribing is standard in psychiatry, with a significant share of all psychiatric prescriptions in the United States are written off-label.¹⁰

Each client's program includes clinician consultations, ketamine treatments, one-on-one guide coaching sessions, and unlimited guide messaging. Treatment takes place in your own home, and sessions are supervised remotely through the Mindbloom platform.

A peer treatment monitor is required to be present during every session to ensure safety. Mindbloom's model embeds ketamine therapy within a defined treatment framework that includes clinical oversight, preparation, and integration support.

A Mindbloom program includes:

• Clinician consults: Medical evaluation and ongoing dosage support.
• Ketamine treatments: Sublingual or subcutaneous options for at-home sessions.
• Guide coaching: One-on-one preparation and integration support.
• Community access: Unlimited Group Integration Circles.
• Bloombox: An experiential toolkit with session essentials.
• Mindbloom App: Comprehensive programs with custom soundscapes.

Mindbloom offers both sublingual and subcutaneous administration. This makes it the only at-home provider with a subcutaneous option.

How Do Mindbloom and Spravato Treat Depression?

Both Mindbloom's ketamine and Spravato's esketamine target the glutamate system, which is the brain's primary excitatory neurotransmitter pathway. Conventional antidepressants typically modulate serotonin or norepinephrine over several weeks.

In contrast, ketamine-based treatments temporarily modulate NMDA receptor signaling. This modulation triggers a cascade of downstream effects, including increased AMPA receptor activation and enhanced synaptogenesis.

This process supports neuroplasticity, which is the brain's ability to form and strengthen new neural connections. Many people report noticeable symptom improvement within hours or days of their first session.

The mechanism cascade includes:

• NMDA modulation: Temporarily adjusts signaling between brain regions.
• Glutamate surge: Increases availability of the excitatory neurotransmitter.
• AMPA activation: Stimulates receptors that promote neural growth.
• Synaptogenesis: Helps form new connections between neurons.

More durable and cumulative benefits typically develop over a series of sessions. While racemic ketamine (used by Mindbloom) and esketamine (used in Spravato) have somewhat different receptor binding profiles, the shared mechanism explains why both approaches can produce rapid antidepressant effects.

How Are Mindbloom and Spravato Administered?

Spravato is administered as a nasal spray in a certified clinic. Mindbloom delivers ketamine at home via sublingual tablets or subcutaneous injection.

The administration method affects onset, ketamine bioavailability, and the logistical demands on the patient. Spravato requires repeated clinic visits, whereas Mindbloom's at-home model removes travel friction while maintaining clinical oversight.

Administration methods include:

• Spravato administration: You arrive at a REMS-certified clinic, self-administer the nasal spray under observation, and remain for a two-hour monitoring period.
• Mindbloom sublingual tablets: You hold small tablets between your cheeks and gums for seven minutes, with the ketamine sublingual dose taking effect within 10–15 minutes.
• Mindbloom subcutaneous injection: Mindbloom injections are administered via a small insulin-type needle into the abdomen, with effects beginning in approximately five minutes.

Mindbloom's subcutaneous option offers higher bioavailability and more consistent session intensity compared to sublingual tablets. Both Mindbloom methods require a peer treatment monitor to be present in your home.

Who Is Eligible for Mindbloom vs. Spravato?

Both Mindbloom and Spravato require clinical evaluation before treatment begins, but their eligibility criteria differ. Spravato's eligibility is narrower by regulatory design, while Mindbloom evaluates a broader range of conditions.

Spravato is FDA-approved specifically for adults with treatment-resistant depression. This is defined as an inadequate response to at least two oral antidepressants in the current depressive episode.

Spravato is also approved for major depressive disorder with acute suicidal ideation. Contraindications include aneurysmal vascular disease and a history of intracerebral hemorrhage.

Mindbloom clinicians evaluate candidates for depression, anxiety, PTSD, and related conditions. A qualifying diagnosis is required, but prior antidepressant failure is not a prerequisite for treatment.

While ketamine is not FDA approved for PTSD, licensed clinicians frequently prescribe it off-label for PTSD based on clinical evidence and patient needs. Ketamine therapy may not be appropriate for individuals with uncontrolled hypertension, active psychosis, or certain cardiac conditions, which the clinician evaluates during screening.

Mindbloom vs. Spravato Effectiveness and Published Research

Direct comparison across treatment modalities can be complicated by differences in study design, patient populations, and outcome instruments. In the case of Mindbloom and Spravato, however, there is a useful and direct comparison available: both treatments have published real-world studies using the same depression instrument (PHQ-9) in comparable patient populations.

Real-world head-to-head data

In the largest published real-world study of Mindbloom's protocol (Mathai et al., 2024, n=11,441), 28.1% of patients reached PHQ-9 remission at four weeks, with a mean PHQ-9 reduction of 7.6 points (a 49% reduction from a baseline of 15.5).²

In the largest published real-world study of Spravato (Marci et al., 2025, n=163), 18.4% of patients reached PHQ-9 remission at three to six months, with a mean PHQ-9 reduction of 4.4 points (a 29% reduction from a baseline of 15.0).¹²

Both studies used the same instrument, the same remission threshold, and comparable baseline severity. The remaining differences are duration (four weeks vs. three to six months) and magnitude.

Head-to-head research between formulations

The largest meta-analysis comparing racemic ketamine (the formulation Mindbloom uses) and esketamine (the formulation in Spravato) pooled 1,877 patients across 24 randomized controlled trials (Bahji et al., 2021).¹³ In that analysis, racemic ketamine produced response rates approximately 2.2 times higher than esketamine and remission rates approximately 2.5 times higher; esketamine had approximately 80% higher dropout than racemic ketamine across the included trials.

The only direct head-to-head randomized controlled trial of racemic ketamine vs. esketamine in treatment-resistant depression (Correia-Melo et al., 2020, n=63) found the two formulations non-inferior at 24 hours; at seven days, racemic ketamine trended toward more prolonged antidepressant effect.²¹

Spravato's evidence base in context

Spravato's effect size in its one positive efficacy trial (TRANSFORM-2) was d=0.30, classified as "small" by standard clinical research conventions.¹⁵ Spravato is also studied and labeled as an adjunct to a newly initiated oral antidepressant rather than as monotherapy, which is a meaningful structural difference from the Mindbloom protocol.

Mindbloom's published outcomes

Mindbloom's published outcomes data shows:

• Depression improvement: In a peer-reviewed study of 11,441 patients, 89% of clients reported improvement in symptoms, with a 56.4% response rate and a 28.1% remission rate at four weeks.²
• Anxiety improvement: In the same study, 89% of participants reported improvement in anxiety symptoms, with a 56.1% response rate.²
• PTSD improvement: In a real-world analysis of 374 PTSD program completers, 92.2% reported symptom improvement, with a 79.7% response rate.³

Methodology note

Mindbloom's published studies are real-world cohort studies; Spravato's pivotal trials are placebo-controlled randomized trials. Each design has methodological strengths and limitations. Real-world studies capture broader patient populations but lack a placebo comparator. Randomized trials isolate drug effect more cleanly but use stricter patient selection. The Marci 2025 real-world Spravato study (BMC Psychiatry) is the cleanest available like-for-like comparator to Mindbloom's published outcomes because it uses the same PHQ-9 instrument and a comparable community-practice population.

Mindbloom vs. Spravato Side Effects and Safety

Both Mindbloom and Spravato can produce temporary acute side effects related to their shared pharmacology. Reported rates differ substantially between the two treatments in the published research.

Reported side effect rates

In Spravato's longest published safety study (SUSTAIN-2, n=802), the most common treatment-emergent adverse events among esketamine patients were:¹⁹

• Dizziness: 32.9%
• Dissociation: 27.6%
• Nausea: 25.1%
• Headache: 24.9%

Of the 802 patients in SUSTAIN-2, 76 (9.5%) discontinued esketamine due to adverse events, and 55 (6.9%) experienced serious treatment-emergent adverse events. Approximately 25% of patients completed the one-year maintenance phase; approximately 75% did not.

In Mindbloom's published study (Mathai 2024, n=11,441), side effects were reported at approximately 4–5% of sessions, serious adverse events at fewer than 0.1% of patients, and discontinuation due to adverse events at 0.4%.²

Methodology context

Mindbloom's adverse event reporting (patient-initiated) and SUSTAIN-2's adverse event capture (protocol-driven, actively solicited at every clinic visit) use different methodologies, and some of the gap between reported rates reflects this difference rather than purely clinical reality. SUSTAIN-2 is also a one-year exposure study, while Mathai 2024 captures a four-week treatment course, so cumulative exposure differs. These caveats notwithstanding, the published rates differ by approximately an order of magnitude on the dimensions where both studies report comparable data.

Acute effects and management

Common acute effects of either treatment can include dissociation, sedation, dizziness, nausea, and temporary increases in blood pressure. Dissociation refers to a sense of detachment from your body or environment. It is a known pharmacological effect of ketamine and is not inherently dangerous when experienced under appropriate supervision.

Spravato manages safety through in-clinic administration, with the mandatory two-hour observation period including blood pressure monitoring at specified intervals.

Mindbloom manages safety through medical screening, the required in-home peer treatment monitor, clinician oversight before and after each session, and integration support. Individuals with uncontrolled hypertension, active psychosis, or certain cardiac conditions may not be appropriate candidates for either treatment, which is why cardiovascular screening is a mandatory part of intake.

Ketamine is a Schedule III medication with dependence potential, primarily documented in chronic, unsupervised recreational use patterns involving frequent, high doses.11 Mindbloom mitigates this risk through clinical screening, controlled dispensing of exact therapeutic doses, and ongoing clinician oversight.

Mindbloom vs. Spravato Cost, Insurance, and Access

Spravato and Mindbloom operate under fundamentally different payment and access models. The best fit depends on your insurance situation, proximity to a certified clinic, and how you weigh direct cost against time and convenience.

Cost and Insurance

Spravato is more commonly covered by commercial insurance and Medicare Part B than generic ketamine, which can meaningfully reduce out-of-pocket costs for patients who qualify. Prior authorization is typically required, and copays vary by plan, but for patients with eligible coverage, Spravato may be the more affordable option on a per-session basis.

Without insurance coverage, real-world Spravato treatment costs (medication, in-clinic administration, monitoring time, and REMS overhead) can run several thousand dollars per induction course. Mindbloom's pricing is transparent and structured in monthly installments, regardless of insurance status.

Mindbloom is typically paid out of pocket and is not covered by most insurance plans directly. All programs are eligible for HSA and FSA funds, and pricing is transparent and structured in monthly installments:

• 6-Session Program: $1,290 total, paid as $430 per month for 3 months.
• 12-Session Program: $2,220 total, paid as $370 per month for 6 months.
• 18-Session Program: $2,970 total, paid as $330 per month for 9 months.

Convenience and Access

Spravato must be administered at a REMS-certified clinic, and availability depends on proximity to a participating facility. During the induction phase, sessions are typically scheduled twice weekly for four weeks, followed by weekly or biweekly maintenance. Each visit requires travel to the clinic, a mandatory two-hour post-dose observation period, and arranged transportation home, as patients cannot drive after treatment.

Mindbloom's at-home model eliminates clinic scheduling, travel, and the need for a driver. Sessions take place in your own home on your own schedule, supervised remotely through the Mindbloom platform. A peer treatment monitor is required to be present, but treatment can be scheduled around your daily life rather than around clinic availability.

Mindbloom vs. Spravato Care Model and Support

Ketamine-based treatment can be delivered as medication alone or as part of a comprehensive therapeutic program. The distinction matters for long-term outcomes and the post-session transition.

Spravato's care model centers on medication administration and observation. Treatment is administered by healthcare staff at a certified clinic, with clinical interaction focusing on the dosing session itself.

Ongoing psychiatric care, such as talk therapy or daily medication management, typically occurs separately through the patient's existing providers. Spravato does not include built-in coaching or integration support as part of its standard offering.

Mindbloom provides a protocol-driven program where ketamine is one component of a broader therapeutic framework. Each program includes clinician consultations, one-on-one guide coaching sessions for preparation, and unlimited Group Integration Circles.

Integration is the process of making meaning from the ketamine experience and applying insights to daily life. In Mindbloom's model, integration is a built-in component designed to support durable change, rather than an optional add-on.

Which Option Is Right for You — Mindbloom or Spravato?

Both options represent clinically grounded approaches to ketamine-based treatment. The right fit depends on your diagnosis, your insurance situation, your treatment setting preferences, and which body of clinical evidence resonates most with your priorities.

Spravato may be a better fit if you:

• Have been diagnosed with treatment-resistant depression (inadequate response to two or more antidepressants) and need an FDA-approved medication on the label for insurance or documentation reasons.
• Have commercial or Medicare Part B coverage that meaningfully reduces your out-of-pocket cost for Spravato.
• Prefer or require in-person medical supervision during every session.
• Have a REMS-certified treatment center within reasonable travel distance.
• Have the time and logistical support to make multiple in-clinic visits per week during induction, plus a two-hour post-dose observation at each visit.

Mindbloom may be a better fit if you:

• Are seeking treatment for depression, anxiety, PTSD, burnout, grief, or related conditions, regardless of whether prior medications have been tried.
• Prefer at-home treatment without the scheduling, travel, and post-dose monitoring demands of in-clinic visits.
• Want a comprehensive program with clinician oversight, coaching, integration, and community support built in.
• Are paying out of pocket and want transparent, predictable monthly pricing.
• Want a treatment grounded in the largest published real-world ketamine outcomes studies to date (n=11,441; n=1,247) and the racemic formulation favored in the largest head-to-head meta-analysis of the two ketamine formulations (n=1,877).^1,2,13
• Want the option of subcutaneous administration for higher bioavailability than sublingual tablets.

The right choice depends on your diagnosis, your insurance situation, your treatment setting preference, and how much support you want surrounding each session. For patients without a TRD diagnosis or without Spravato insurance coverage, Mindbloom's at-home protocol offers a broader eligibility model, transparent pricing, and a different evidence base. A conversation with a licensed clinician can help clarify which path aligns with your specific clinical needs.

Disclaimer and Safety Information

IMPORTANT SAFETY INFORMATIONKetamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and is not appropriate for patients with uncontrolled hypertension, psychotic disorders, or substance use disorders. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

‍OFF-LABEL USE DISCLOSUREKetamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.